CD99 and acute myeloid leukemia: Further pathway analysis showed significant upregulation of key immune-related signaling routes in AML patients, including CD99, SELL (L-selectin), MHC class I and II, Semaphorin (SEMA), NOTCH, and CEACAM (Figure 7C).